Novel neurohormonal insights with therapeutic potential in chronic heart failure

Future Cardiology

Volumn 6, Issue 3, 2010, Pages 361-372

  Dalzell, Jonathan R ^b   Jackson, Colette E ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

Author keywords

(pro)renin receptor; ACE2; Apelin; Chronic heart failure; Neurohormones; Pathophysiology; Relaxin; Reninangiotensin system; Urocortin

Indexed keywords

ALISKIREN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; APELIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NEUROHORMONE; PRORENIN; PRORENIN RECEPTOR; RELAXIN; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; DISEASE MODEL; DOWN REGULATION; DRUG MECHANISM; HEART FAILURE; HEART HEMODYNAMICS; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASODILATATION;

ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HEART FAILURE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, CELL SURFACE; RELAXIN; RENIN; UROCORTINS;

EID: 77952520250     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.13     Document Type: Review

References (151)

1. Mosterd A, Hoes AW: Clinical epidemiology of heart failure. Heart 93, 1137-1146 (2007).
2. Berry C, Murdoch DR, McMurray JJ: Economics of chronic heart failure. Eur. J. Heart Fail. 3, 283-291 (2001).
3. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 3, 315-322 (2001).
4. Jhund PS, Macintyre K, Simpson CR et al.: Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 119, 515-523 (2009).
5. Tatemoto K, Hosoya M, Habata Y et al.: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251, 471-476 (1998).
6. O'Dowd BF, Heiber M, Chan A et al.: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136, 355-360 (1993).
7. Hosoya M, Kawamata Y, Fukusumi S et al.: Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275, 21061-21067 (2000).
8. Vickers C, Hales P, Kaushik V et al.: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843 (2002).
9. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF: Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 146 (1), 231-236 (2005).
10. Kleinz MJ, Davenport AP: Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul. Pept. 118, 119-125 (2004).
11. Chen MM, Ashley EA, Deng DX et al.: Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108, 1432-1439 (2003). First report of the downregulation of the myocardial apelin-APJ system in human chronic heart failure (CHF).
12. Katagampola SD, Maguire JJ, Matthewson SR, Davenport AP: 125I- (Pyr1) apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Brit. J. Pharmacol. 132, 1255-1260 (2001).
13. Kleinz MJ, Skepper JN, Davenport AP: Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul. Pept. 126, 233-240 (2005).
14. Kuba K, Zhang L, Imai Y et al.: Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload. Circ. Res. 101, E32-E42 (2007). First description of the impact of apelin knockout on the heart.
15. Ashley EA, Powers J, Chen M et al.: The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65, 73-82 (2005).
16. De Mota N, Reaux-Le Goazigo A, El Messari S et al.: Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc. Natl Acad. Sci. USA 101, 10464-10469 (2004).
17. Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, Llorens-Cortes C: Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int. 74, 486-494 (2008).
18. Ernst KV, Ashley EA, Charo D et al.: Apelin regulates cardiac contractility and rescues neurohormonal heart failure (abstract). Circulation 114, II 66 (2006).
19. Szokodi I, Tavi P, Foldes G et al.: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates contractility Circ. Res. 91, 434-400 (2002).
20. Farkasfalvi K, Stagg MA, Coppen SR et al.: Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem. Biophys. Res. Comm. 357, 889-895 (2007).
21. Jia YX, Pan CS, Zhang J et al.: Apelin protects myocardial injury induced by isoproterenol in rats. Regul. Pept. 133, 147-154 (2006).
22. Berry MF, Pirolli TJ, Jayasankar V et al.: Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110, 187-193 (2004).
23. Iwanaga Y, Kihara Y, Takenaka H, Kita T: Down-regulation of cardiac apelin system in hypertrophied and failing hearts:possible role of the angiotensin II-angiotensin type I receptor system. J. Mol. Cell Cardiol. 41, 798-806 (2006).
24. Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T: Effects of olmesartan on apelin/APJ and Akt/eNOS pathway in Dahl rats with end-stage heart failure. J. Cardiovasc. Pharmacol. 55, 83-88 (2010).
25. Weir RA, Chong KS, Dalzell JR et al.: Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur. J. Heart Fail. 11, 551-558 (2009).
26. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP: Pyr1apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54, 598-604 (2009).
27. Japp AG, Cruden NL, Amer DA et al.: Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 52, 908-913 (2008). First report of the vascular actions of apelin in vivo in humans.
28. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA: Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur. J. Heart Fail. 8, 355-360 (2006). First description of the reduction in circulating apelin levels in a large cohort of advanced CHF patients.
29. Francia P, Salvati A, Balla C et al.: Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur. J. Heart Fail. 9, 306-309 (2007).
30. Goetze JP, Rehfield JF, Carlsen J et al.: Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept. 133, 134-138 (2006).
31. Fodie;ldes G, Horkay F, Szokodi I et al.: Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem. Biophys. Res. Commun. 308, 480-485 (2003).
32. Mullens W, Bartunek J, Wilson Tang WH et al.: Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm 5, 52-59 (2008).
33. Boonprasert P, Lailerd N, Chattipakorn N: Urocortins in heart failure and ischemic heart disease. Int. J. Cardiol. 127, 307-312 (2008).
34. Kimura Y, Takahashi K, Totsune K et al.: Expression of urocortin and corticotropinreleasing factor receptor subtypes in the human heart. J. Clin. Endocrinol. Metab. 87, 340-346 (2002).
35. Hsu SY, Hsueh AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 7, 605-611 (2001).
36. Takahashi K, Totsune K, Murakami O et al.: Expression of urocortin III/stresscopin in human heart and kidney. J. Clin. Endocrinol. Metab. 89, 1897-1903 (2004).
37. Reyes TM, Lewis K, Perrin MH et al.: Urocortin II: a member of the corticotropinreleasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl Acad. Sci. USA 98, 2843-2848 (2001).
38. Lewis K, Li C, Perrin MH et al.: Identification of urocortin III, an additional member of the corticotropinreleasing factor (CRF) family with high affnity for the CRF2 receptor. Proc. Natl Acad. Sci. USA 98, 7570-7575 (2001).
39. Wiley KE, Davenport AP: CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br. J. Pharmacol. 143, 508-514 (2004).
40. Parkes DG, Vaughan J, Rivier J, Vale W, May CN: Cardiac inotropic actions of urocortin in conscious sheep. Am. J. Physiol. 272, H2115-H2122 (1997).
41. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T: Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J. Endocrinol. 169, 177-183 (2001).
42. Nishikimi T, Miyata A, Horio T et al.: Urocortin, a member of the corticotropinreleasing factor family, in normal and diseased heart. Am. J. Physiol. Heart Circ. Physiol. 279, H3031-H3039 (2000).
43. Ikeda K, Tojo K, Sato S et al.: Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem. Biophys. Res. Commun. 250, 298-304 (1998).
44. Agnello D, Bertini R, Sacco S, Meazza C, Villa P, Ghezzi P: Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am. J. Physiol. 275, E757-E762 (1998).
45. Anker SD, von Haehling S: Inflammatory mediators in chronic heart failure: an overview. Heart 90, 464-470 (2004). (Pubitemid 38406929)
46. Chen CY, Doong ML, Rivier JE, Tacheacute; Y: Intravenous urocortin II decreases blood pressure through CRF (2) receptor in rats. Regul. Pept. 113, 125-130 (2003).
47. Mackay KB, Stiefel TH, Ling N, Foster AC: Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat. Eur. J. Pharmacol. 469, 111-115 (2003).
48. Grossini E, Molinari C, Mary DA, Marino P, Vacca G: The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric oxide-dependent. Eur. J. Pharmacol. 578, 242-248 (2008).
49. Coste SC, Kesterson RA, Heldwein KA: Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat. Genet. 24, 403-409 (2000).
50. Charles CJ, Jardine DL, Nicholls MG, Rademaker MT, Richards AM: Urocortin 1 exhibits potent inhibition of cardiac sympathetic nerve activity in conscious sheep. J. Hypertens. 26, 53-60 (2008).
51. Charles CJ, Jardine DL, Rademaker MT, Richards AM: Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep. J. Endocrinol. 204, 181-189 (2010).
52. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM: Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur. Heart J. 26, 2055-2062 (2005).
53. Rademaker MT, Cameron VA, Charles CJ, Richards AM: Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112, 3624-3632 (2005).
54. Rademaker MT, Cameron VA, Charles CJ, Richards AM: Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur. Heart J. 27, 2088-2098 (2006).
55. Bale TL, Hoshijima M, Gu Y et al.: The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc. Natl Acad. Sci. USA 101, 3697-3702 (2004).
56. Rademaker MT, Charles CJ, Richards AM: Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am. J. Physiol. Heart Circ. Physiol. 293, H1536-H1544 (2007).
57. Rademaker MT, Charles CJ, Nicholls MG, Richards AM: Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin. Sci. (Lond.) 114, 635-642 (2008).
58. Rademaker MT, Charles CJ, Nicholls MG, Richards AM: Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Circ. Heart Fail. 2, 532-540 (2009).
59. Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW: Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc. Res. 65, 913-920 (2005).
60. Sanz E, Monge L, Fernaacute;ndez N et al.: Relaxation by urocortin of human saphenous veins. Br. J. Pharmacol. 136, 90-94 (2002).
61. Davis ME, Pemberton CJ, Yandle TG et al.: Urocortin-1 infusion in normal humans. J. Clin. Endocrinol. Metab. 89, 1402-1409 (2004).
62. Davis ME, Pemberton CJ, Yandle TG et al.: Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J. Am. Coll. Cardiol. 49, 461-471 (2007).
63. Ikeda K, Tojo K, Tokudome G et al.: Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. Mol. Cell Biochem. 252, 25-32 (2003).
64. Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM: Plasma urocortin 1 in human heart failure. Circ. Heart Fail. 2, 465-471 (2009).
65. Davis ME, Pemberton CJ, Yandle TG et al.: Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin. Sci. (Lond). 109, 381-388 (2005). Effects of urocortin-I infusion in human CHF.
66. Davis ME, Pemberton CJ, Yandle TG et al.: Urocortin 2 infusion in human heart failure. Eur. Heart J. 28, 2589-2597 (2007). Effects of urocortin-II infusion in human CHF.
67. Park JI, Chang CL, Hsu SY: New insights into biological roles of relaxin and relaxinrelated peptides. Rev. Endocr. Metab. Disord. 6, 291-296 (2005).
68. Kohsaka T, Min G, Lukas G, Trupin S, Campbell ET, Sherwood OD: Identification of specific relaxin-binding cells in the human female. Biol. Reprod. 59, 991-999 (1998). (Pubitemid 28463355)
69. Taylor MJ, Clark CL: Evidence for a novel source of relaxin: atrial cardiocytes. J. Endocrinol. 143, R5-R8 (1994).
70. Hsu SY, Nakabayashi K, Nishi S et al.: Activation of orphan receptors by the hormone relaxin. Science 295, 671-674 (2002).
71. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW: Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc. Res. 57, 395-404 (2003). Description of the effects of relaxin knockout on the heart.
72. Kakouris H, Eddie LW, Summers RJ: Cardiac effects of relaxin in rats. Lancet 339, 1076-1078 (1992).
73. Toth M, Taskinen P, Ruskoaho H: Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart. J. Endocrinol. 150, 487-495 (1996).
74. Bani-Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E: Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br. J. Pharmacol. 116, 1589-1594 (1995).
75. Danielson LA, Sherwood OD, Conrad KP: Relaxin is a potent renal vasodilator in conscious rats. J. Clin. Invest. 103, 525-533 (1999).
76. Massicotte G, Parent A, St-Louis J: Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin. Proc. Soc. Exp. Biol. Med. 190, 254-259 (1989).
77. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K: Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-κB. Circ. Res. 92, 32-40 (2003).
78. Debrah DO, Conrad KP, Danielson LA, Shroff SG: Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. J. Appl. Physiol. 98, 1013-1020 (2005).
79. Zhang J, Qi YF, Geng B et al.: Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 26, 1632-1639 (2005).
80. Bani D, Nistri S, Formigli L, Meacci E, Francini F, Zecchi-Orlandini S: Prominent role of relaxin in improving postinfarction heart remodeling. Ann. NY Acad. Sci. 1160, 269-277 (2009).
81. Du XJ, Xu Q, Lekgabe E et al.: Reversal of cardiac fibrosis and related dysfunction by relaxin. Ann. NY Acad. Sci. 1160, 278-284 (2009).
82. Fisher C, MacLean M, Morecroft I et al.: Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation 106, 292-295 (2002).
83. Smith MC, Danielson LA, Conrad KP, Davison JM: Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J. Am. Soc. Nephrol. 17, 3192-3197 (2006).
84. Dschietzig T, Richter C, Bartsch C et al.: The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 15, 2187-2195 (2001).
85. Fisher C, Berry C, Blue L, Morton J J, McMurray J: N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89, 879-881 (2003).
86. Dschietzig T, Teichman S, Unemori E et al.: Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J. Card. Fail. 15, 182-190 (2009). First report of relaxin infusion in human CHF.
87. Teerlink JR, Metra M, Felker GM et al.: Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding Phase IIb study. Lancet 373, 1429-1439 (2009). Randomized trial of relaxin infusion versus placebo in acutely decompensated heart failure.
88. Nguyen G: Renin/prorenin receptors. Kidney Int. 69, 1503-1506 (2006).
89. Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H: Determinants of inter individualvariation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro) renin levels in humans. J. Hypertens. 16, 853-862 (1998).
90. Deinum J, Rønn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA: Increase in serum prorenin precedes onset of microalbuminuria in patients with insulindependent diabetes mellitus. Diabetalogia 42, 1006-1010 (1999).
91. Danser AH, van den Dorpel MA, Deinum J et al.: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy J. Clin. Endocrinol. Metab. 68, 160-167 (1989).
92. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 312, 1412-1417 (1985).
93. Danser AH, van Kesteren CA, Bax WA et al.: Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 96, 220-226 (1997). Report of increased myocardial prorenin levels in human CHF.
94. Sealey JE, Moon C, Laragh JH et al.: Plasma prorenin in normal, hypertensive and anephric patients and its effect on renin measurements. Circ. Res. 40, 141-145 (1977).
95. Nguyen G, Delarue F, Burckle C et al.: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002). First description of the (pro) renin receptor.
96. Batenburg WW, Krop M, Garrelds IM et al.: Prorenin is the endogenous agonist of the (pro) renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro) renin receptor. J. Hypertens. 25, 2441-2453 (2007).
97. Burckleacute; CA, Jan Danser AH, Mudie;ller DN et al.: Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 47, 552-556 (2006).
98. Amsterdam A, Nissen RM, Sun Z, Swindell EC, Farrington S, Hopkins N: Identification of 315 genes essential for early zebrafish development. Proc. Natl Acad. Sci. USA 101, 12792-12797 (2004).
99. Ramser J, Abidi FE, Burckle CA et al.: A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor. Hum. Mol. Genet. 14, 019-027 (2005).
100. Hirose T, Hashimoto M, Totsune K et al.: Association of (pro) renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study. Am. J. Hypertens. 22, 294-299 (2009).
101. Suzuki F, Hayakawa M, Nakagawa T et al.: Human prorenin has 'gate and handle' regions for its non-proteolytic activation. J. Biol. Chem. 278, 22217-22222 (2003).
102. Huang Y, Wongamorntham S, Kasting J et al.: Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 69, 105-113 (2006).
103. Ichihara A, Suzuki F, Nakagawa T et al.: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptordeficient mice. J. Am. Soc. Nephrol. 17, 1950-1961 (2006).
104. Huang Y, Noble NA, Zhang J, Xu C, Border WA: Renin-stimulated TGF-β 1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 72, 45-52 (2007).
105. Saris J J, Hoen PA, Garrelds IM et al.: Prorenin induces intracellular signalling I cardiomyocytes independent of angiotensin II. Hypertension 48, 564-571 (2006).
106. Sakoda M, Ichihara A, Kaneshiro Y et al.: (Pro) renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens. Res. 30, 1139-1146 (2007).
107. He M, Zhang L, Shao Y et al.: Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 606, 155-161 (2009).
108. Nabi AH, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F: 'Decoy peptide' region (RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin binding to the (pro) renin receptor. Int. J. Mol. Med. 24, 83-89 (2009).
109. Ichihara A, Hayashi M, Kaneshiro Y et al.: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J. Clin. Invest. 114, 1128-1135 (2004).
110. Takahashi H, Ichihara A, Kaneshiro Y et al.: Regression of nephropathy developed in diabetes by (pro) renin receptor blockade. J. Am. Soc. Nephrol. 18, 2054-2061 (2007).
111. Ichihara A, Kaneshiro Y, Takemitsu T et al.: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47, 894-900 (2006). Demonstration of the role of the (pro) renin receptor in the development of myocardial fibrosis in spontaneously hypertensive rats.
112. Satofuka S, Ichihara A, Nagai N et al.: Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest. Ophthalmol. Vis. Sci. 47, 2686-2692 (2006).
113. Feldt S, Batenburg WW, Mazak I et al.: Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51, 682-688 (2008).
114. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN: The putative (pro) renin receptor blocker HRP fails to prevent (pro) renin signaling. J. Am. Soc. Nephrol. 19, 743-748 (2008).
115. Packer M, Medina N, Yushak M, Lee WH: Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients. Br. Heart J. 54, 298-304 (1985).
116. McKenna F, Davison AM: Renin and b-blockade: prorenin and aldosterone may explain the controversy. Clin. Nephrol. 25, 149-154 (1986).
117. Feldman DL, Jin L, Xuan H et al.: Effects of aliskiren on blood pressure, albuminuria, and (pro) renin receptor expression in diabetic TG (mRen-2) 27 rats. Hypertension 52, 130-136 (2008).
118. McMurray JJ, Pitt B, Latini R et al.; for the Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008).
119. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221-229 (2007).
120. Donoghue M, Hsieh F, Baronas E et al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1-E9 (2000).
121. Danilczyk U, Penninger JM: Angiotensinconverting enzyme II in the heart and the kidney. Circ. Res. 98, 463-471 (2006).
122. Lambert DW, Yarski M, Warner FJ et al.: Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280, 30113-30119 (2005).
123. Crackower MA, Sarao R, Oudit GY et al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828 (2002).
124. Nakamura K, Koibuchi N, Nishimatsu H et al.: Candesartan ameliorates cardiac dysfunction observed in angiotensinconverting enzyme 2-deficient mice. Hypertens. Res. 31, 1953-1961 (2008).
125. Gurley SB, Allred A, Le TH et al.: Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 116, 2218-2225 (2006).
126. Kassiri Z, Zhong J, Guo D et al.: Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail. 2, 446-455 (2009).
127. Yamamoto K, Ohishi M, Katsuya T et al.: Deletion of angiotensin- converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47, 718-726 (2006).
128. Huentelman MJ, Grobe JL, Vazquez J et al.: Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol. 90, 783-790 (2005).
129. Der Sarkissian S, Grobe JL, Yuan L et al.: Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology Hypertension 51, 712-718 (2008).
130. Burrell LM, Risvanis J, Kubota E et al.: Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 26, 369-375 (2005).
131. Goulter AB, Goddard MJ, Allen JC, Clark KL: ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2, 19 (2004).
132. Ferrario CM, Jessup J, Chappell MC et al.: Effect of angiotensin- converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605-2610 (2005).
133. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43, 970-976 (2004).
134. Kaiqiang Ji, Minakawa M, Fukui K, Suzuki Y, Fukuda I: Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Ther. Adv. Cardiovasc. Dis. 3, 103-111 (2009).
135. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S: Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin-aldosterone system. J. Am. Coll. Cardiol. 52, 750-754 (2008). First description of the increased circulating angiotensin-converting enzyme (ACE) 2 levels in human CHF.
136. Epelman S, Shrestha K, Troughton RW et al.: Soluble angiotensin- converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J. Card. Fail. 15, 565-571 (2009). First description of the strong prognostic power of ACE2 in human CHF.
137. Fedak PW, Moravec CS, McCarthy PM et al.: Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 113, 238-245 (2006).
138. Wysocki J, Ye M, Rodriguez E et al.: Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55, 90-98 (2010).
139. Santos RA, Castro CH, Gava E et al.: Impairment of in vitro and in vivo heart function in angiotensin- (1-7) receptor MAS knockout mice. Hypertension 47, 996-1002 (2006).
140. Sampaio WO, Nascimento AA, Santos RA: Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am. J. Physiol. Heart Circ. Physiol. 284, H1985-H1994 (2003).
141. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM: Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108, 2141-2146 (2003).
142. Loot AE, Roks AJ, Henning RH et al.: Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105, 1548-1550 (2002).
143. Ferreira AJ, Jacoby BA, Arauacute;jo CA et al.: The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 292, H1113-H1119 (2007).
144. Sasaki S, Higashi Y, Nakagawa K, Matsuura H, Kajiyama G, Oshima T: Effects of angiotensin (1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension 38, 90-94 (2001).
145. Roks AJ, van Geel PP, Pinto YM et al.: Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 34, 296-301 (1999).
146. Ueda S, Masumori-Maemoto S, Ashino K et al.: Angiotensin (1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35, 998-1001 (2000).
147. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM: Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J. Hypertens. 14, 799-805 (1996). (Pubitemid 26187416)
148. Iyer SN, Ferrario CM, Chappell MC: Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31, 356-361 (1998).
149. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM: Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31, 699-705 (1998).
150. Davie AP, McMurray JJ: Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 34, 457-460 (1999).
151. Krum H, Abraham WT: Heart failure. Lancet 373, 941-955 (2009).